Jazz Pharmaceuticals Signs Exclusive Licensing Deal for Epilepsy Treatment with Saniona

Saniona and Jazz Pharmaceuticals have signed an exclusive licensing deal for an epilepsy treatment. Jazz Pharmaceuticals will commercialize Saniona's epilepsy treatment, with Saniona retaining development and manufacturing rights. The deal is expected to provide a significant revenue stream for Saniona and expand Jazz Pharmaceuticals' product portfolio. Financial terms were not disclosed.

Saniona and Jazz Pharmaceuticals have signed an exclusive licensing deal for an epilepsy treatment. Jazz Pharmaceuticals will commercialize Saniona's epilepsy treatment, with Saniona retaining development and manufacturing rights. The deal is expected to provide a significant revenue stream for Saniona and expand Jazz Pharmaceuticals' product portfolio. Financial terms were not disclosed.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) have entered into a global license agreement, granting Jazz exclusive worldwide rights to develop and commercialize SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications. The agreement aims to overcome the limitations of non-selective Kv7-targeting compounds [1].

Under the terms of the deal, Saniona will receive an upfront payment of US$42.5 million. Additionally, Saniona is eligible for development and regulatory milestone payments, commercial milestone payments based on net sales thresholds, and tiered royalties on future net sales [1]. Jazz Pharmaceuticals will lead and fund further development, regulatory submissions, and global commercialization activities.

The collaboration leverages Jazz's leading position in epilepsy and its strong track record of advancing clinical development programs and commercializing novel therapies in neuroscience, positioning SAN2355 as a promising option for epilepsy and neurological conditions [1]. Saniona's CEO, Thomas Feldthus, stated that the partnership aligns with their mission to improve outcomes for those affected by neurological and psychiatric disorders.

SAN2355 is a preclinical, selective small molecule activator of Kv7.2/Kv7.3 potassium channels, a mechanism validated for seizure suppression. Prior Kv7-targeting agents have demonstrated clinical efficacy but have been limited by adverse events associated with off-target activation. SAN2355's unique selectivity for Kv7.2/Kv7.3 supports its potential as a best-in-class treatment for epilepsy [1].

This licensing deal is expected to provide a significant revenue stream for Saniona and expand Jazz Pharmaceuticals' product portfolio in the epilepsy treatment space. Financial terms were not disclosed, but the deal highlights the companies' commitment to developing life-changing medicines for people with serious diseases.

References:
[1] Jazz Pharmaceuticals plc. (2025). Jazz Pharmaceuticals enters exclusive licensing agreement with Saniona to develop and commercialize SAN2355. Retrieved from https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-enters-exclusive-licensing-agreement